Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected RCC Receiving Immunotherapy (SAMURAI)
February 6, 2024
The Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI) trial compares standard immunotherapy to immunotherapy combined with radiation for patients not suited for surgery. It's an open-label trial, meaning participants and doctors know the treatments. After treatment, patients are closely monitored for side effects and treatment response. Scan the QR code for enrollment information.
Read the Full Video Transcript
Narrator: This video is an overview of a new study for patients with metastatic kidney cancer who cannot have surgery. When kidney cancer leaves the kidney and spreads to other parts of the body, it is called metastatic kidney cancer. The main treatment for metastatic kidney cancer is immunotherapy and anti-angiogenic agents. Immunotherapy is medication infused directly into the bloodstream. The treatment activates your immune system to fight the kidney cancer. Anti-angiogenic medications are pills taken by mouth. They stop the formation of blood vessels that bring oxygen and nutrients to the tumor. This may slow the growth and spread of the tumor.
In addition to these medications, surgery is sometimes recommended for the primary tumor in the kidney. This surgery is called a nephrectomy and doctors remove the entire kidney. The benefits of such an operation are unknown in patients receiving immunotherapy. Some patients are reluctant to have surgery or they are not able to have surgery, either because the tumor is too large or because they have other health problems that would make surgery too risky.
For these patients, minimally invasive external beam radiation therapy may be a helpful treatment for kidney cancer. Radiation therapy is high energy X-rays targeted at the tumor in the kidney. Radiation is delivered with high precision to protect other organs in the area. In this study, patients who are not recommended for surgery will be randomly assigned to receive either standard immunotherapy or immunotherapy combined with radiation. Neither doctors nor patients decide which treatment they will receive on trial. The study is not blinded, which means doctors and patients will know which treatments they receive. After treatment, doctors will continue to monitor patients for side effects and response to treatment. For more information on how to enroll on this study, scan the QR code shown here.
Narrator: This video is an overview of a new study for patients with metastatic kidney cancer who cannot have surgery. When kidney cancer leaves the kidney and spreads to other parts of the body, it is called metastatic kidney cancer. The main treatment for metastatic kidney cancer is immunotherapy and anti-angiogenic agents. Immunotherapy is medication infused directly into the bloodstream. The treatment activates your immune system to fight the kidney cancer. Anti-angiogenic medications are pills taken by mouth. They stop the formation of blood vessels that bring oxygen and nutrients to the tumor. This may slow the growth and spread of the tumor.
In addition to these medications, surgery is sometimes recommended for the primary tumor in the kidney. This surgery is called a nephrectomy and doctors remove the entire kidney. The benefits of such an operation are unknown in patients receiving immunotherapy. Some patients are reluctant to have surgery or they are not able to have surgery, either because the tumor is too large or because they have other health problems that would make surgery too risky.
For these patients, minimally invasive external beam radiation therapy may be a helpful treatment for kidney cancer. Radiation therapy is high energy X-rays targeted at the tumor in the kidney. Radiation is delivered with high precision to protect other organs in the area. In this study, patients who are not recommended for surgery will be randomly assigned to receive either standard immunotherapy or immunotherapy combined with radiation. Neither doctors nor patients decide which treatment they will receive on trial. The study is not blinded, which means doctors and patients will know which treatments they receive. After treatment, doctors will continue to monitor patients for side effects and response to treatment. For more information on how to enroll on this study, scan the QR code shown here.